December 17th, 2025
Kallyope, a late-stage biotechnology company leveraging unique insights into neural signaling pathways to develop innovative therapies for health challenges faced by hundreds of millions of people globally, today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference to be held January 12-15 in San Francisco, CA.
44th Annual J.P. Morgan Healthcare Conference Presentation Details
Presentation Date: Tuesday, January 13, 2026
Presentation Time: 11:00 AM PST
Presenter: Jay Galeota, Chief Executive Officer and President
Location: San Francisco, CA
During the presentation, Mr. Galeota will provide an overview of the Company’s lead programs, including elismetrep (K-304), an oral Transient Receptor Potential Melastatin 8 (TRPM8) antagonist for the acute treatment of migraine, expected to begin pivotal studies in mid-2026, and K-554, which targets a non-incretin peptide receptor for weight loss and glucose control and will enter Phase 1 clinical studies in mid- 2026.